O

ver the past couple of years, drug makers have increasingly explored outcomes-based contracting as a way to convince payers to cover their medicines. Basically, this notion revolves around the idea that an insurer will get a drug at a lower cost if a patient does not benefit as planned. But not all deals are likely to deliver, and a new analysis argued that an agreement offered by Amgen (AMGN) is a notable example.

To wit, Amgen sells Repatha, a new type of cholesterol medicine approved in 2015 to treat patients who struggle to control cholesterol using statins, particularly those with an inherited disorder known as familial hypercholesterolemia. Around the same time, Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) won regulatory approval to market a competing treatment.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.